Literature DB >> 30107759

Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps.

Enrico Heffler1,2, Luca Malvezzi3, Monica Boita4, Luisa Brussino4, Armando De Virgilio3, Matteo Ferrando5, Francesca Puggioni1,2, Francesca Racca1, Niccolò Stomeo1,2, Giuseppe Spriano3, Giorgio Walter Canonica1,2.   

Abstract

INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common and quality-of-life impacting disorder, with an underlying immunological mechanism similar to other conditions such as eosinophilic asthma or atopic eczema. Areas covered: This review article summarizes the most recent evidence on the main immunological mechanisms involved in the pathogenesis and the perpetuation of CRSwNP, with a particular focus on the key role of epithelium-derived inflammation as a consequence of the interaction with the airborne environment. Expert commentary: The increase in knowledge of the immunology of CRSwNP leads to the development of therapeutical strategies based upon the use of biologic agents that, according to a personalized and precision medicine approach, will provide each single patient with the most suitable immunological treatment.

Entities:  

Keywords:  Chronic rhinosinusitis; epithelium; immunology; inflammation; nasal polyps

Mesh:

Substances:

Year:  2018        PMID: 30107759     DOI: 10.1080/1744666X.2018.1512407

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  7 in total

1.  Th17/Treg cells regulated by interleukin 6 in the pathogenesis of chronic rhinosinusitis with nasal polyps.

Authors:  Haiyang Li; Yongle Wang; Jianting Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-11       Impact factor: 2.503

2.  Role of P2X7R in eosinophilic and non‑eosinophilic chronic rhinosinusitis with nasal polyps.

Authors:  Yan Wang; Shan Chen; Wenwen Wang; Jianjun Chen; Weijia Kong; Yanjun Wang
Journal:  Mol Med Rep       Date:  2021-05-26       Impact factor: 2.952

3.  Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.

Authors:  Enrico Heffler; Fabiana Saccheri; Marta Bartezaghi; Giorgio Walter Canonica
Journal:  Clin Transl Allergy       Date:  2020-06-26       Impact factor: 5.871

Review 4.  Interleukin-5 in the Pathophysiology of Severe Asthma.

Authors:  Corrado Pelaia; Giovanni Paoletti; Francesca Puggioni; Francesca Racca; Girolamo Pelaia; Giorgio Walter Canonica; Enrico Heffler
Journal:  Front Physiol       Date:  2019-12-17       Impact factor: 4.566

5.  Elevated ALCAM Expression Associated with Endotypes and Postoperative Recurrence in Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Hua Zhang; Shaobing Xie; Ruohao Fan; Fengjun Wang; Zhihai Xie; Weihong Jiang
Journal:  J Inflamm Res       Date:  2022-02-15

6.  Long-lasting clinical, radiological and immunological remission of severe nasal polyposis by means of 'reboot' surgery.

Authors:  Luca Malvezzi; Francesca Pirola; Armando De Virgilio; Enrico Heffler
Journal:  BMJ Case Rep       Date:  2020-04-02

7.  Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.

Authors:  Nicola Lombardo; Corrado Pelaia; Marco Ciriolo; Marcello Della Corte; Giovanna Piazzetta; Nadia Lobello; Pasquale Viola; Girolamo Pelaia
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.